Company Filing History:
Years Active: 2023-2024
Title: Leon Van Berkom: Innovator in ENPP1 Inhibition
Introduction
Leon Van Berkom is a notable inventor based in Nijmegen, Netherlands. He has made significant contributions to the field of medicinal chemistry, particularly in the development of inhibitors for ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). With a total of 2 patents, his work is paving the way for new therapeutic approaches.
Latest Patents
Van Berkom's latest patents include "Heterocyclic inhibitors of ENPP1" and "Imino sulfanone inhibitors of ENPP1." The first patent focuses on triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1, detailing methods for using these compounds to treat diseases mediated by ENPP1. The second patent discusses sulfoximine-based inhibitors of ENPP1, also aimed at treating diseases associated with this enzyme.
Career Highlights
Leon Van Berkom is currently associated with Volastra Therapeutics, Inc., where he continues to innovate in the field of drug development. His expertise in medicinal chemistry has positioned him as a key player in the research and development of novel therapeutic agents.
Collaborations
He collaborates with talented individuals such as Derek A Cogan and Sarah Bettigole, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Leon Van Berkom's work in developing ENPP1 inhibitors showcases his commitment to advancing medical science. His patents reflect a deep understanding of medicinal chemistry and a dedication to improving therapeutic options for patients.